Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages 517-525

  Ladhani, Shamez N ^a   Andrews, Nick J ^a   Waight, Pauline ^a   Borrow, Ray ^b   Slack, Mary P E ^a   Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

comorbidity; pneumonia; serotype distribution; vaccine effectiveness; vaccine impact

Indexed keywords

PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CEREBRAL PALSY; CHILD; CHILDHOOD DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COMORBIDITY; DRUG USE; GENERAL PRACTITIONER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PNEUMOCOCCAL INFECTION; PNEUMONIA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SEROTYPE; UNITED KINGDOM; VACCINATION; COMPLICATION; EPIDEMIOLOGICAL MONITORING; FEMALE; IMMUNOLOGY; MALE; PNEUMOCOCCAL INFECTIONS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMORBIDITY; ENGLAND; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUESTIONNAIRES; VACCINATION; WALES;

EID: 84893250465     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit791     Document Type: Article

References (19)

1. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11:760-8.
2. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011; 29:9127-31.
3. Pebody RG, Hippisley-Cox J, Harcourt S, Pringle M, Painter M, Smith G. Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999-2005. Epidemiol Infect 2008; 136:360-9.
4. UK Department of Health. Chapter 25: Pneumococcal. In: Salisbury D, Ramsay M, Noakes K, eds. Immunisation against infectious disease-The Green Book, 2006 updated ed. Norwick: TSO (The Stationary Office), 2011:295-313.
5. Borrow R, Heath PT, Siegrist CA. Use of pneumococcal polysaccharide vaccine in children: what is the evidence? Curr Opin Infect Dis 2012; 25:292-303.
6. Van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65:17-24.
7. Ladhani SN, Slack MP, Andrews NJ, Waight PA, Borrow R, Miller E. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis 2013; 19:61-8.
8. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 1999; 103: E28.
9. Hjuler T, Wohlfahrt J, Staum KM, Koch A, Biggar RJ, Melbye M. Risks of invasive pneumococcal disease in children with underlying chronic diseases. Pediatrics 2008; 122:e26-32.
10. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113:443-9.
11. Hsu KK, Shea KM, Stevenson AE, Pelton SI. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 2010; 29:289-93.
12. Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics 2010; 126:e9-17.
13. Hsu KK, Shea KM, Stevenson AE, Pelton SI. Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era. Pediatr Infect Dis J 2011; 30:251-3.
14. Grau I, Ardanuy C, Calatayud L, et al. Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden(1)-ST306. PLoS One 2012; 7:e42595.
15. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30:6802-8.
16. Obando I, Munoz-Almagro C, Arroyo LA, et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis 2008; 14:1390-7.
17. Eltringham G, Kearns A, Freeman R, et al. Culture-negative childhood empyema is usually due to penicillin-sensitive Streptococcus pneumoniae capsular serotype 1. J Clin Microbiol 2003; 41:521-2.
18. Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis 2002; 34:434-40.
19. Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid (2007-2011). Pediatr Infect Dis J 2012; 32:656-61.